Overview of clinical studies of childhood acute lymphoblastic leukemia for more than ten years by the Japanese Children's Cancer and Leukemia Study Group.
Overview of clinical studies of childhood acute lymphoblastic leukemia for more than ten years by the Japanese Children's Cancer and Leukemia Study Group.
复制标题
日本儿童癌症和白血病研究小组十余年儿童急性淋巴细胞白血病临床研究综述。
DOI：
10.3109/08880019709030881
复制
发表时间：
1997
影响因子：
1.7
通讯作者：
I. Sekine
中科院分区：
文献类型：
--
作者：
S. Koizumi;T. Fujimoto;T. Oka;S. Watanabe;A. Kikuta;T. Tsuchiya;T. Matsushita;K. Asami;T. Yanase;J. Mimaya;S. Ohta;M. Miyake;K. Nishikawa;T. Furuyama;Y. Yamamura;Y. Takaue;T. Ninomiya;T. Shimokawa;A. Iwai;Y. Ishida;N. Ariyoshi;K. Kimura;K. Kawakami;T. Gushiken;I. Sekine
自 1981 年以来，儿童癌症和白血病研究小组 (CCLSG) 制定了一系列治疗儿童急性淋巴细胞白血病 (ALL) 的方案。在 811 方案（1981-1983）的第一个随机对照研究中，对传统的每日 6-巯基嘌呤和甲氨蝶呤与两种药物的脉冲疗法进行了比较。显示了脉冲方案的优越性。在接下来的841方案（1984-1987）中，对诱导治疗期间的两种药物和三种药物进行了比较。三种药物方案显着提高了无事件生存率 (EFS)。在874方案（1987-1990）中，随机比较了有或没有颅脑照射的两种方案，对于标准风险组，两种方案之间没有显着差异。为了进一步提高 EFS 率，从 1991 年 1 月开始实施了针对风险群体的方案 911。系列 CCLSG 方案的生命表分析显示，随着 EFS 率的增加，整体 ALL 的结局逐渐改善； 811 协议 14 年时为 41.4% +/- 3.6%，841 协议 11 年时为 51.3% +/- 3.5%，874 协议 8 年时为 56.7% +/- 3.1%，最近的 911 协议 4 年时为 78.2% +/- 3.1%。
Since 1981, the Children's Cancer and Leukemia Study Group (CCLSG) has developed a series of protocols for treatment of acute lymphoblastic leukemia (ALL) in childhood. In the first randomized controlled study of the 811 protocol (1981-1983) a comparison of conventional daily 6-mercaptopurine and methotrexate with a pulsed regimen of the two drugs was performed. The superiority of the pulsed regimen was shown. In the next 841 protocol (1984-1987) a comparison of two drugs and three drugs during induction therapy was conducted. The three-drug regimen resulted in a significantly higher event-free survival (EFS) rate. In the 874 protocol (1987-1990) two regimens with or without cranial irradiation were randomly compared, and there was no significant difference between the two regimens for the standard-risk group. To further improve the EFS rate a risk group-directed protocol 911 was conducted starting in January 1991. Life-table analysis of serial CCLSG protocols revealed that the outcome of overall ALL has gradually improved with an increase of the EFS rate; 41.4% +/- 3.6% at 14 years for the 811 protocol, 51.3% +/- 3.5% at 11 years for the 841 protocol, 56.7% +/- 3.1% at 8 years for the 874 protocol, and 78.2% +/- 3.1% at 4 years for the more recent 911 protocol.
影响因子：
45.3
作者：
SCHORIN, MA;BLATTNER, S;SALLAN, SE
通讯作者：
SALLAN, SE
影响因子：
158.5
作者：
CLAVELL, LA;GELBER, RD;SALLAN, SE
通讯作者：
SALLAN, SE
影响因子：
45.3
作者：
Smith, M;Arthur, D;Ungerleider, R
通讯作者：
Ungerleider, R